Pharmacological inhibition of these enzymes may achieve desirable anti-tumor effects via AXIN stabilization with subsequent effective attenuation of downstream β-catenin signaling, and offer a new approach for the treatment of multiple cancers that over express TNKS1 or TNKS2. This evidence concerns the gene TNKS2 and cancer.